Clinical Trial Update: Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety and feasibility of Nivolumab-IRDye800CW in patients with head and neck squamous cell carcinoma; the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• IRDye800CW (IRDye800CW)
• nivolumab (nivolumab)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Hnscc, Head and Neck | Phase 1 | Status: NOT_YET_RECRUITING